Home » Millennium Gobbles Up Predictive Medicine, Eyes Pharmacogenomics Future

Millennium Gobbles Up Predictive Medicine, Eyes Pharmacogenomics Future

Mar 09, 2000
Premium

C

AMBRIDGE, Mass.--Millennium Pharmaceuticals announced that it will acquire the remaining shares of its Millennium Predictive Medicine subsidiary that it does not already own, making it a wholly owned subsidiary. The company said that the transaction, a stock-for-stock exchange, will align more closely Millennium’s therapeutic and predictive medicine discovery and development efforts.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Faster Profiles

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

Standards Needed

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

Conflict Search

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

This Week in Science

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.

What's Popular?

In Informatics

  1. Shivom, Lifebit Partner on DNA Analysis Platform for Clinical Trials

  2. 10x Genomics Acquires Spatial Transcriptomics

  3. OnRamp, Active Motif Ink Epigenetic Data Analysis Partnership

  4. BiomX Inks IBD Biomarker Deal With Janssen

  5. Paradigm4 Pushes Multi-Omics Translational Informatics

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.